Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov 1;109(11):3785-3789.
doi: 10.3324/haematol.2024.285359.

FLT3 inhibitors potentially improve response rates in acute myeloid leukemia harboring t(6;9)(DEK::NUP214): the Mayo Clinic experience

Clifford M Csizmar  1 , Antoine N Saliba  1 , Patricia T Greipp  2 , Hassan Alkhateeb  1 , Kebede H Begna  1 , James M Foran  3 , Naseema Gangat  1 , William J Hogan  1 , C Christopher Hook  1 , Mark R Litzow  1 , Abhishek A Mangaonkar  1 , Jeanne M Palmer  4 , Animesh Pardanani  1 , Mithun V Shah  1 , Ayalew Tefferi  1 , Mehrdad Hefazi Torghabeh  1 , Alexandra P Wolanskyj-Spinner  1 , Mrinal M Patnaik  1 , Scott H Kaufmann  5 , Aref Al-Kali  6
Affiliations

FLT3 inhibitors potentially improve response rates in acute myeloid leukemia harboring t(6;9)(DEK::NUP214): the Mayo Clinic experience

Clifford M Csizmar et al. Haematologica. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Overall survival in t(6;9)(DEK::NUP214) acute myeloid leukemia and compared to European Leukemia Network risk groups. (A) The median overall survival (mOS) of the entire cohort. (B-F) mOS of fms-like tyrosine kinase 3 (FLT3) wild-type versus FLT3 internal tandem duplications (FLT3-ITD) cases (B); FLT3-ITD-positive cases receiving a FLT3 inhibitor (FLT3i) versus those that did not (C); t(6;9) acute myeloid leukemia (AML) patients undergoing allogeneic hematopoietic cell transplantation (alloHCT) versus those who did not (D); cases with wild-type FLT3 who underwent allogeneic hematopoietic cell transplantation (alloHCT) versus those who did not (E); and those with a FLT3-ITD mutation who underwent alloHCT compared to those who did not (F). (G) Comparison of OS in the t(6;9) AML cohort versus the ELN favorable, intermediate, and adverse-risk groups. (H) Comparison of OS in the t(6;9) AML subset who underwent alloHCT versus the European Leukemia Network (ELN) favorable, intermediate, and adverse-risk groups who also underwent alloHCT. (I) Comparison of OS in the t(6;9) AML cohort versus age-restricted subgroups of the comparison cohort; the median (range) ages of the 3 subgroups are 38 (18-55), 50 (18-60), and 56 (18-65) years (y), respectively. In (G-I), P values depict the comparison between the t(6;9) AML cohort and the color-matched subgroup of the comparison cohort. All survival times are denoted as median (95% confidence interval) in months (mo).
See this image and copyright information in PMC

References

    1. Döhner H, Wei AH, Appelbaum FR, et al. . Diagnosis and management of AML in adults: 2022 ELN recommendations from an international expert panel. Blood. 2022;140(12):1345-1377.. - PubMed
    1. Slovak ML, Gundacker H, Bloomfield CD, et al. . A retrospective study of 69 patients with t(6;9)(p23;q34) AML emphasizes the need for a prospective, multicenter initiative for rare ‘poor prognosis’ myeloid malignancies. Leukemia. 2006;20(7):1295-1297. - PubMed
    1. Fang H, Yabe M, Zhang X, et al. . Myelodysplastic syndrome with t(6;9)(p22;q34.1)/DEK-NUP214 better classified as acute myeloid leukemia? A multicenter study of 107 cases. Mod Pathol. 2021;34(6):1143-1152. - PubMed
    1. Oyarzo MP, Lin P, Glassman A, Bueso-Ramos CE, Luthra R, Medeiros LJ. Acute myeloid leukemia with t(6;9)(p23;q34) is associated with dysplasia and a high frequency of flt3 gene mutations. Am J Clin Pathol. 2004;122(3):348-358. - PubMed
    1. Visconte V, Shetty S, Przychodzen B, et al. . Clinicopathologic and molecular characterization of myeloid neoplasms with isolated t(6;9)(p23;q34). Int J Lab Hematol. 2017;39(4):409-417. - PMC - PubMed

LinkOut - more resources